8-K: INmune Bio Reports Positive Alzheimer's Imaging Data, MSC Study

INmune Bio announced new neuroimaging data from its Phase 2 Alzheimer's trial showing slowed neurodegeneration and highlighted a peer-reviewed study supporting its CORDStrom platform.

Summary

• New neuroimaging data from the Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer's disease (AD) and elevated neuroinflammation showed a trend towards slowed neurodegeneration progression.
• Using PerpPD+ MRI imaging analysis, investigators observed attenuated increases in cortical disarray, an imaging hallmark associated with neurodegeneration, in dose-compliant ADi participants.
• These results reinforce previously reported directional improvements across biological, cognitive, and neuropsychiatric endpoints for XPro1595.
• A recently published peer-reviewed article in Cytotherapy, co-authored by INmune Bio's lead scientist for CORDStrom R&D, Dr. Nikita M. Patel, provided an overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies.
• The peer-reviewed article provides important scientific background for the future development of INmune Bio's CORDStrom platform, which is initially being developed for recessive dystrophic epidermolysis bullosa (RDEB).

Sentiment

Score: 7

Explanation: The filing presents positive early-stage clinical data for XPro1595 in Alzheimer's disease, showing a trend towards slowed neurodegeneration, and highlights scientific validation for its CORDStrom platform. However, the clinical results are described as a 'trend' rather than statistically significant, and both programs are still in clinical development with future funding needs identified as a risk.

Positives

• XPro1595 Phase 2 MINDFuL trial showed a trend towards slowed neurodegeneration progression in early AD patients with high inflammatory burden.
• PerpPD+ neuroimaging data indicated attenuated increases in cortical disarray, suggesting a reduction in neurodegeneration at the microstructural level.
• These results reinforce previously reported directional improvements across biological, cognitive, and neuropsychiatric endpoints for XPro1595.
• The data further validate the strategy of targeting inflammation-driven AD, a large and underserved subset representing a significant unmet need and potential commercial opportunity.
• A peer-reviewed publication highlights the therapeutic potential of MSC therapies, providing scientific background and supporting the CORDStrom platform.
• INmune Bio's lead scientist for CORDStrom R&D, Dr. Nikita M. Patel, was a lead author on the peer-reviewed article, enhancing scientific credibility and internal expertise.

Negatives

• The neuroimaging results for XPro1595 showed a 'trend towards slowed neurodegeneration progression' and 'trend for reduced cortical disarray,' indicating the findings are not yet statistically significant.

Risks

• Clinical trials are in early stages, and there is no assurance that any specific outcome will be achieved.
• No assurance that product candidates (CORDStrom, XPro1595, INKMune) will be approved by the US Food and Drug Administration (FDA) or any other regulatory body.
• Risks and uncertainties relating to the Company's ability to produce more drug for clinical trials.
• The availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies, and future product commercialization.
• Risks related to the Company's business, research, product development, regulatory approval, marketing, and distribution plans and strategies.

Future Outlook

Additional MRI analyses from the MINDFuL trial for XPro1595 are ongoing and expected to be presented in 2026, providing a broader picture of tissue-level impact. The Company believes the totality of data generated to date positions XPro1595 as a promising first-in-class disease-modifying therapy for the large subset of Alzheimer's patients with elevated neuroinflammation. A Biologics License Application (BLA) and Marketing Authorization Application (MAA) for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB) are expected to be filed in 2026. The peer-reviewed article on MSC therapies provides scientific background for future development of the CORDStrom platform beyond RDEB.

Management Comments

• Dr. CJ Barnum, Head of Neuroscience at INmune Bio: "These PerpDP+ data represent one of the clearest signals yet that selectively neutralizing soluble TNF can interrupt the neurodegenerative cascade at its microstructural root in AD driven by inflammation."
• Dr. CJ Barnum, Head of Neuroscience at INmune Bio: "We are excited to analyze the remaining imaging data and to report on this at subsequent meetings and in publications."
• Dr. Steven Chance, CEO of Oxford Brain Diagnostics: "XPro1595 is one of the pioneering interventions to examine the powerful role the innate immune system plays in Alzheimers disease pathology."
• Dr. Steven Chance, CEO of Oxford Brain Diagnostics: "In the dose compliant participants, CDM showed a trend for reduced cortical disarray, indicating lower neurodegeneration."
• Dr. Mark Lowdell, INmune Bio CSO: "Stromal cell therapies are an important clinical advancement that may have significant impact in multiple indications including inflammation, immunomodulation, and wound healing."
• Dr. Mark Lowdell, INmune Bio CSO: "Nikitas role within INmuneBio supports continued advancement in the knowledge base on MSCs. We believe her contributions as one of the senior authors to this article, and the insightful questions asked by the panel, will have an important impact on the development of the use of MSCs in general in addition to the ongoing development of our CORDStrom platform."

Industry Context

The Alzheimer's disease market represents a significant unmet need, especially for subsets like inflammation-driven AD, where current therapies are limited and none specifically target innate immune dysfunction. XPro1595 aims to fill this gap. Mesenchymal stromal cell (MSC) therapies, like CORDStrom, are an important clinical advancement with potential broad impact in inflammation, immunomodulation, and wound healing, indicating a growing area of research and development in the biotechnology sector.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials continue to show positive results and lead to regulatory approvals. Risk of dilution if substantial additional funding requires equity raises.
• Patients (Alzheimer's): Hope for a new disease-modifying therapy, especially for those with inflammation-driven AD, a currently underserved population.
• Patients (RDEB): Potential for a new treatment option with the CORDStrom platform.
• Scientific Community: Contribution to the understanding of innate immune dysfunction in neurodegenerative diseases and the therapeutic potential of MSCs.

Next Steps

• Analyze remaining MRI imaging data from the MINDFuL trial for XPro1595.
• Present additional MRI analyses from the MINDFuL trial in 2026.
• File a Biologics License Application (BLA) and Marketing Authorization Application (MAA) for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB) in 2026.
• Continue development of the CORDStrom platform for future applications beyond RDEB.

Key Dates

Recommendation

While the early neuroimaging data for XPro1595 in Alzheimer's disease show a promising trend towards slowed neurodegeneration, the results are not yet statistically significant, and the program remains in Phase 2. The CORDStrom platform also shows future potential with an expected BLA/MAA filing in 2026. However, the company explicitly states the need for 'substantial additional funding' as a risk, which could lead to dilution. Given the early stage of development and funding uncertainties, a 'hold' recommendation is appropriate, awaiting further statistically significant clinical data and clarity on financing.

Keywords

Alzheimer's disease, neuroinflammation, XPro1595, Phase 2 trial, neurodegeneration, mesenchymal stromal cells, CORDStrom, biotechnology, clinical-stage, innate immune dysfunction, sTNF inhibitor, RDEB